Thomas Lechner Msc Phd Email & Phone Number

Cambridge, Massachusetts, Us

In this role, I cultivate a culture of growth for our US Medical Affairs organization, including partnering with Global Medical Affairs and Commercial Leadership to align strategies and business plans. I work closely with the CEO/President and CCO to build and grow the US organization and operations. Additionally, I lead staffing and training, as well as identify and secure opportunities for KOL-investigator interactions and engagement.Highlights:• Spearheaded the development and buildout of the US Medical Affairs organization and infrastructure to support late-stage development and commercialization of our oncology and specialty care products. • Established and enhanced our team culture and fostered a robust research community to support IIT, Phase III, Phase IV and RWE programs

Planegg, Bayern, De

During this time, I guided strategy, organizational planning and development, and staffing for the US Medical Affairs department. I collaborated frequently with global Medical Affairs leaders to ensure the alignment of our strategies while also enabling customized solutions for each market/region. In addition, I secured and sustained relationships with KOLs; lead our Medical Information, Medical Education, and Medical Communications & Publications teams; and directed Phase IV, post-marketing, and RWE evidence gathering. Highlights:• Established US Medical Director’s Office and built out Medical Affairs Infrastructure from the ground up. • Maintained open lines of communication with KOLs during COVID-19 to ensure ongoing operations. • Developed and trained staff, as well as provided ongoing leadership to support successful product launches.

Ingelheim Am Rhein, Rhineland-Palatinate, De

Upon my transition to Boehringer-Ingelheim USA, I directed the Clinical Development and Medical Affairs (CDMA) organization for the US Oncology therapeutic area, which included strategic planning and ongoing leadership and guidance of organizational teams. Highlights:• Collaborated with global teams to improve the representation and engagement of US CDMA in early pipeline project planning, development, and prioritization. • Selected as the Interim Head/VP of the Specialty Care organization to manage the 200-person US CDMA organization while continuing to lead the Oncology team. • Navigated a large-scale business transformation and a related change in leadership by reorganizing the division, maintaining morale, and ensuring positive change management within budgetary guidelines. • Completed an internal three-part Executive Development Rotation Program, which included assignments of up to one year as Director of Market Access, Director of Marketing (Oncology), and Oncology Sales Consultant.

Ingelheim Am Rhein, Rhineland-Palatinate, De

In this role, I managed the Medical Advisor, Scientific Relations, and late-stage Clinical Development teams for various products. I also reviewed our Medical Affairs strategy to ensure alignment with our brand strategy and organizational goals. I provided ongoing medical support and guidance to stakeholders across the US, EU, and APAC, as well as collaborated with internal teams and external partners to plan for global launches and ensure operational readiness across regions and markets. Highlights:• Served as Global Team Leader, Clinical Development and Senior Global Medical Advisor for Afatinib and Global Team Leader, Medical Affairs during the Giotrif/Gilotrif product launch. • Named global Medical Affairs Launch Readiness Lead for Giotrif/Gilotrif. • Developed and implemented support processes for NPU/EAP and Investigator-Initiated Studies (IIS) across therapeutic areas, a new process for the organization.

New York, New York, Us

With Pfizer Oncology, I oversaw Medical Affairs for both our US and global pharmaceutical launches for the treatment of Breast Cancer, Gastrointestinal Stromal Tumors (GIST), and Soft Tissue Sarcomas. I collaborated with KOLs across this space to secure buy-in, build credibility, and expand our community network. Highlights:• Guided the rollout of Sutent both within US and global markets, as well as Axitinib. • Directed safety management activities for GIST and Renal Cell Cancer (RCC) therapeutics

New York, New York, Us

As SVP of Medical Education & Communications, I led analysis, identification, and capture of new opportunities, as well as directed strategy for growing existing opportunities across the pharmaceutical sector. Serving as a core member of the senior leadership team, I spearheaded the launch of large-scale educational initiatives. I was promoted to this position after serving as Medical Director of the Oncology division through November 2004.

Postdoctoral Fellow, Epigenetics

Doctor Of Philosophy - Phd, Molecular Genetics

Master Of Science - Ms, Microbiology, General